Raymond F. Schinazi, PhD, DSc
Dr. Schinazi is widely considered one of the most prolific antiviral drug developers of all time and is responsible for the discovery and/or development of five drugs used to treat HIV, HBV and HCV. Dr. Schinazi is currently the Frances Winship Professor of Pediatrics, Director of the Laboratory of Biochemical Pharmacology, and Co-Director of the HIV Cure Scientific Working Group within the NIH-sponsored Emory University Center for AIDS Research. His laboratory develops approaches to treat infections caused by HIV, HBV, HCV, herpes, influenza, Zika, West Nile, chikungunya and dengue virus, among others.
Insights from 40 years of research at Emory led Dr. Schinazi to found multiple successful biotechnology companies, including Pharmasset, Inc. (VRUS; acquired by Gilead for $11.4 billion in 2012), Idenix Pharmaceuticals (IDIX; acquired by Merck for $3.9 billion in 2014) and Triangle Pharmaceuticals (VIRS; acquired by Gilead for $464 million in 2003). In 2014, Dr. Schinazi also led the merger of his namesake RFS Pharma with Cocrystal Pharma (COCP), where he now serves as Chairman of the Board. In addition to his work at Emory University, Dr. Schinazi spent 35 years at the Atlanta Department of Veterans Affairs (later receiving the VA Lab’s highest honor for his service). He is also Governing Trustee for the Foundation of AIDS Research, on the Board of the Global Virus Network, and serves on the Boards of Brace Pharmaceuticals, Gliknik Inc., and reViral, Ltd.